Is Celldex Therapeutics Stock a Good Investment?
Celldex Therapeutics Investment Advice | CLDX |
- Examine Celldex Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Celldex Therapeutics' leadership team and their track record. Good management can help Celldex Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Celldex Therapeutics' business and its evolving consumer preferences.
- Compare Celldex Therapeutics' performance and market position to its competitors. Analyze how Celldex Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Celldex Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Celldex Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Celldex Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Celldex Therapeutics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Celldex Therapeutics Stock
Researching Celldex Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 100.0% of the company shares are held by institutions such as insurance companies. The book value of Celldex Therapeutics was currently reported as 11.85. The company recorded a loss per share of 2.58. Celldex Therapeutics last dividend was issued on the 11th of February 2019. The entity had 1:15 split on the 11th of February 2019.
To determine if Celldex Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Celldex Therapeutics' research are outlined below:
| Celldex Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 6.88 M. Net Loss for the year was (141.43 M) with loss before overhead, payroll, taxes, and interest of (137.06 M). | |
| Celldex Therapeutics currently holds about 356.82 M in cash with (107.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.63. | |
| Celldex Therapeutics has a poor financial position based on the latest SEC disclosures |
Celldex Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Celldex Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Celldex Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Celldex Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.63 B.Basic technical analysis of Celldex Stock
As of the 30th of January, Celldex Therapeutics shows the Risk Adjusted Performance of 0.0124, downside deviation of 3.26, and Mean Deviation of 2.56. Celldex Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Celldex Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Celldex Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Celldex Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Celldex Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Celldex Therapeutics' Outstanding Corporate Bonds
Celldex Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Celldex Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Celldex bonds can be classified according to their maturity, which is the date when Celldex Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| CELULOSA ARAUCO Y Corp BondUS151191BD46 | View | |
| CELARA 3875 02 NOV 27 Corp BondUS151191BB89 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Celldex Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Celldex Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0124 | |||
| Market Risk Adjusted Performance | 0.0268 | |||
| Mean Deviation | 2.56 | |||
| Semi Deviation | 3.2 | |||
| Downside Deviation | 3.26 | |||
| Coefficient Of Variation | 16949.21 | |||
| Standard Deviation | 3.35 | |||
| Variance | 11.21 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.03) | |||
| Total Risk Alpha | (0.29) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0168 | |||
| Maximum Drawdown | 17.16 | |||
| Value At Risk | (4.90) | |||
| Potential Upside | 4.48 | |||
| Downside Variance | 10.62 | |||
| Semi Variance | 10.27 | |||
| Expected Short fall | (2.86) | |||
| Skewness | (0.08) | |||
| Kurtosis | 0.5327 |
| Risk Adjusted Performance | 0.0124 | |||
| Market Risk Adjusted Performance | 0.0268 | |||
| Mean Deviation | 2.56 | |||
| Semi Deviation | 3.2 | |||
| Downside Deviation | 3.26 | |||
| Coefficient Of Variation | 16949.21 | |||
| Standard Deviation | 3.35 | |||
| Variance | 11.21 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.03) | |||
| Total Risk Alpha | (0.29) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0168 | |||
| Maximum Drawdown | 17.16 | |||
| Value At Risk | (4.90) | |||
| Potential Upside | 4.48 | |||
| Downside Variance | 10.62 | |||
| Semi Variance | 10.27 | |||
| Expected Short fall | (2.86) | |||
| Skewness | (0.08) | |||
| Kurtosis | 0.5327 |
Consider Celldex Therapeutics' intraday indicators
Celldex Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Celldex Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 69416.87 | |||
| Daily Balance Of Power | 0.4785 | |||
| Rate Of Daily Change | 1.04 | |||
| Day Median Price | 25.2 | |||
| Day Typical Price | 25.3 | |||
| Price Action Indicator | 0.76 | |||
| Period Momentum Indicator | 0.89 |
Celldex Stock media impact
Far too much social signal, news, headlines, and media speculation about Celldex Therapeutics that are available to investors today. That information is available publicly through Celldex media outlets and privately through word of mouth or via Celldex internal channels. However, regardless of the origin, that massive amount of Celldex data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Celldex Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Celldex Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Celldex Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Celldex Therapeutics alpha.
Celldex Therapeutics Corporate Management
| Ronald Pepin | Chief Bus. Officer and Sr. VP | Profile | |
| Patrick Till | Senior Communications | Profile | |
| Prof Schlessinger | CoFounder Board | Profile | |
| Diane MD | Senior Officer | Profile | |
| Margo MD | Senior Affairs | Profile |
Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.